[tetramer]

It also only looks at HER2 and CA15-3 (aka MUC1) expression - what about breast cancers that don't express either of these?

I realize this is an early technology and I think it should continue to be explored, but I would anticipate that if compared head to head with screening mammograms, it would be inferior.

For patients with relapsed disease, this kind of technology would be neat to non-invasively re-assess biomarker status but as a screening tool, I find it lacking (and certainly a positive screening will require dedicated imaging and biopsy anyway).